Engineered immune cells take on Hard-to-Treat myeloma
NCT ID NCT07333430
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new treatment called HBI0101 CAR-T for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack myeloma cells, and then infusing them back. The study aims to find a safe dose and see if it can shrink tumors, but it is still in the early stages of research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HBI0101 CAR-T cells (a patient's own immune cells modified to target cancer)
What this could lead to
If it works, this could point toward a new treatment option for multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 60 participants, so it is primarily testing safety. The treatment may not work well, and there are risks like severe immune reactions or side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hadassah MO, Jerusalem, 9574869
RECRUITINGJerusalem, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact